Small molecule drug discovery and antibody humanization
Small molecule drug discovery
Our Centre for Therapeutics Discovery collaborates with academic researchers from any institution on small molecule drug discovery projects.
You can access our expertise in assay development, computational and medicinal chemistry. We have a large compound library and screening hits can be returned to you for further investigation. We also aim to promote our collective success by publishing results from our collaborations in high-profile journals.
Therapeutic antibodies
Our Therapeutic Antibody Group, part of the Centre for Therapeutics Discovery, collaborates with academic scientists to generate therapeutic antibodies.
You could access our expertise in antibody humanization. The
Therapeutic Antibody Group has substantial antibody engineering
experience. It has humanized over 40 antibodies, of which 11 have been
progressed to the clinic, and 2 (Actemra® and Tysabri®) are on the
market
In addition to creating new therapeutic antibodies, we may
also be able to provide you with useful research reagents and
opportunities to publish in high-profile journals.
What we look for
We are constantly on the lookout for new and interesting drug or therapeutic antibody targets. If you have a target that you think may be suitable, please get in touch.
Who to contact
Scientists at MRC Units and Institutes: Please contact your Business Manager, or Contact Us and we’ll put you in touch.
Scientists at non-MRC institutions: Please either contact your institution's technology transfer office, or visit our Call for Targets website.
News feed
Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
The University of Leicester is recruiting for an MRCT-supported Research Fellow
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.